Document:

<PAGE>   1
                                                                   EXHIBIT 10.47

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                             DATED 11TH OCTOBER 2000

                           (1) EVANS VACCINES LIMITED

                                   (2) AVIRON

                            -----------------------

                              AMENDED AND RESTATED

                              CONTRACT MANUFACTURE

                                    AGREEMENT

                            -----------------------

                                LATHAM & WATKINS
                                 99 BISHOPSGATE
                                 LONDON EC2M 3XF

                            TEL: +44 (0) 20 7710 1000
                            FAX: +44 (0) 20 7374 4460

<PAGE>   2
[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                            Page
                                                                            ----
<S>     <C>                                                                 <C>
1.      AMENDMENT AND RESTATEMENT............................................ 1

2.      DEFINITIONS AND INTERPRETATION....................................... 1

3.      CONSIDERATION........................................................ 3

4.      PROFIT SHARE PAYMENTS................................................ 3

5.      CURRENCY............................................................. 4

6.      [***]................................................................ 4

7.      RESTRICTIVE COVENANT................................................. 5

8.      ANNOUNCEMENTS AND PUBLICITY.......................................... 5

9.      NOTICES.............................................................. 5

10.     COUNTERPARTS......................................................... 6

11.     VARIATION............................................................ 7

12.     COSTS................................................................ 7

13.     SEVERANCE............................................................ 7

14.     WAIVERS.............................................................. 7

15.     APPLICABLE LAW AND JURISDICTION...................................... 7

16.     [***]................................................................ 7

17.     ASSIGNMENT........................................................... 8

18.     [***]................................................................ 8
</TABLE>

                                       i

<PAGE>   3

THIS AGREEMENT is made the 11th day of October 2000.

BETWEEN:

(1)     EVANS VACCINES LIMITED (registered in England and Wales under Company
        Number: 3970089) the registered office of which is at Florey House,
        Robert Robinson Avenue, Oxford, Oxfordshire OX4 4GA ("EVANS"); and

(2)     AVIRON (registered in Delaware) the registered office of which is at 297
        North Bernardo Avenue, Mountain View, California 94043, United States of
        America ("AVIRON").

WHEREAS:

(A)     Pursuant to an amended and restated contract manufacture agreement dated
        7th June 1999 and made between Medeva Pharma Limited ("MEDEVA") and
        Aviron (the "CMA"), Medeva agreed, inter-alia, to manufacture the
        Intermediate Product (as defined below) for Aviron.

(B)     Pursuant to an agreement dated 7th September 2000 the Evans has acquired
        from Medeva the business carried on at the premises situated in Gaskill
        Road, Speke, Liverpool, of the manufacture, assembly and packaging of
        pharmaceutical products, or components thereof (the "Medeva Sale
        Agreement").

(C)     On 28th September 2000, being the date of completion of the Medeva Sale
        Agreement, the CMA was assigned from Medeva to Evans, in accordance with
        its terms.

(D)     Evans and Aviron now wish to amend and restate the CMA as provided in
        this Agreement.

In consideration of the mutual covenants set forth herein the parties agree as
follows.

1.      AMENDMENT AND RESTATEMENT

        The parties hereby amend and restate the CMA to read in full as set
        forth below and each of the parties agrees that the remaining provisions
        of the CMA, as are not reflected in this Agreement, are hereby
        terminated and that neither party shall have any further rights,
        obligations or liabilities in respect thereof.

2.      DEFINITIONS AND INTERPRETATION

In this Agreement the following words shall have the following meanings:

        "ANNUAL PRODUCTION FORECAST" shall have the meaning ascribed to it in
        the Shared Services Agreement;

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       1
<PAGE>   4

        "ASSOCIATED COMPANIES" means in respect of any party, any company which
        at the relevant time is a subsidiary of that party's ultimate holding
        company or any subsidiary of such a subsidiary where the term subsidiary
        shall have the meaning as defined in section 736 of the Companies Act
        1985 (as amended) and in respect of Aviron any entity that directly or
        indirectly owns, is owned by or is under common ownership with Aviron,
        where own or ownership means direct or indirect possession of at least
        fifty percent (50%) of the outstanding voting securities of a
        corporation or a comparable equity interest in any other type of entity;

        "AVIRON UK" means Aviron UK Limited, a company registered in England and
        Wales (under company number 3854275), a wholly owned subsidiary of
        Aviron;

        "BUSINESS DAY" means any day that is not a Saturday or a Sunday or a
        public holiday in England and Wales;

        "CAIV PRODUCT" means Aviron's live, attenuated, intranasally deliverable
        cold-adapted influenza vaccine;

        "CUSTOMS" means HM Customs & Excise;

        "MILESTONE" means in respect of the following calendar years:

        (a)    2001 - the obtaining by Aviron of its BLA Licence for the
               Vaccine;

        (b)    2002 - achievement of net sales of US$ [***] of the Vaccine;

        (c)    2003 - achievement of net sales of US$ [***] of the Vaccine;

        (d)    2004 - achievement of net sales of US$ [***] of the Vaccine;

        (e)    2005 - achievement of net sales of US$ [***] of the Vaccine;

        (f)    2006 - achievement of net sales of US$ [***] of the Vaccine;

        "NET SALES" shall have the meaning ascribed to it in sub-clause 4.3;

        "PAYMENT DATE" means each of [***];

        "SHARED SERVICES AGREEMENT" means the agreement entered into on the date
        of this Agreement between Evans and Aviron UK relating to the provision
        and sharing of certain services;

        "TRANSACTION AGREEMENTS" shall have the same meaning as that ascribed to
        it in a Master Agreement dated the date of this Agreement made between,
        inter alia, the parties to this Agreement;

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       2
<PAGE>   5

        "VACCINE" means the frozen formulation of Aviron's CAIV Product;

        "VAT" means value added tax under the Value Added Tax Act 1994 ("VATA");

        "WARRANT INSTRUMENTS" means the warrant instruments to be constituted by
        Aviron as referred to in clause 3(c).

3.      CONSIDERATION

        In consideration of Evans agreeing to the amendment and restatement of
        the CMA in accordance with the terms of this Agreement, Aviron agrees
        to:

        (a)    pay to Evans the sum of US$[***] to be paid on the date of this
               Agreement;

        (b)    pay to Evans the sum of US$ [***] to be paid in cleared funds
               within seven days of each Payment Date provided always that such
               sum shall only be payable if the following conditions are met:

               (i)    no [***] pursuant to sub-clause [***] of the [***] has
                      arisen during the year in which the [***] falls;

               (ii)   the [***] for the year in which the [***] falls has been
                      [***]; and

               (iii)  the [***] for the year in which the [***] falls has been
                      [***]; and

        (c)    issue to Evans warrants over 63,162 common shares of Aviron at an
               exercise price of US$ 47.50 per share pursuant to and on the
               terms of the Warrant Instruments, such warrants to be issued to
               Evans within 3 (three) Business Days of the date of this
               Agreement.

4.      PROFIT SHARE PAYMENTS

4.1     As further consideration for Evans agreeing to the amendment and
        restatement of the CMA pursuant to this Agreement, save as provided
        below, within 45 days from the end of each calendar quarter, Aviron
        shall pay to Evans an amount corresponding to [***]% of net sales of the
        Vaccine up to a total of US$ 20 million, provided that any amount of
        said US$ 20 million not paid on [***] shall be due and payable within
        thirty (30) days of such date.

4.2     Aviron's obligation to make any profit share payment to Evans pursuant
        to sub-clause 4.1 shall not commence until such time as Evans's profit
        share entitlement exceeds an amount equal to US$ 1 million together with
        interest on such sum calculated from January 1, 2000 at a rate of [***]
        percent ([***]%) per annum up to the time of grant of the [***] and
        thereafter at a rate of [***] percent ([***]%) per annum up to the date
        Evans' profit share entitlement exceeds such sum. For the avoidance of
        doubt, Evans's total profit share entitlement pursuant to sub-clause 4.1
        shall be reduced by the amount

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       3
<PAGE>   6

        equal to US$ 1 million and interest thereon calculated in accordance
        with this sub-clause 4.2.

4.3     As used herein, "net sales" means the [***] by Aviron or its Associated
        Companies or licensees from persons or entities due to or by reason of
        the [***], less the following [***], but only to the extent such sums
        are otherwise included in the [***], or are [***];

        (a)    [***];

        (b)    [***];

        (c)    [***] other than those described above;

        (d)    [***] (to the extent that the foregoing [***] do not exceed [***]
               percent ([***]%) of the sum of [***] and [***];

        (e)    [***]; and

        (f)    [***].

               [***]  not intended for [***], and made [***] shall not be [***].

4.4     Evans shall be entitled upon reasonable notice and during normal
        business hours to have an independent auditor reasonably acceptable to
        Aviron inspect the financial records of Aviron pertaining to sales of
        the Vaccine to confirm the accuracy of any report or information
        provided to Evans concerning Evans's [***] and Evans and Aviron shall
        make available to said independent auditor such records, in whatever
        form.

        Under no circumstances shall the combined [***] from [***] attributable
        to the factors listed in sub-clauses 4.3 (a) and 4.3 (d) exceed [***]
        percent ([***]%).

4.5     Evans covenants that any sums paid by Aviron to Evans pursuant to this
        clause 4 shall be [***] in accordance with Evans' agreement with Medeva
        Pharma Limited dated 7th September 2000 and in the event that Aviron
        becomes [***] then Evans hereby agrees to [***] provided always that
        Aviron has paid such sums to Evans in accordance with this clause 4.

5.      CURRENCY

        Any sums payable pursuant to this Agreement shall be paid in US$.

6.      [***]

6.1     Any sum payable by Aviron to Evans under this Agreement shall be paid
        [***], save only as may be required by law.

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       4
<PAGE>   7

6.2     If any [***] is required by law to be made [***] under this Agreement,
        Aviron shall [***].

6.3     If Evans obtains a [***] in respect of the said [***] then to the extent
        that Evans is able to [***] as determined by Evans in its absolute
        discretion Evans shall [***] been obtained Provided that Evans will not
        be obliged to make any such [***]to the extent that such [***] available
        to Evans. Evans shall not be obliged to arrange its affairs so as to
        [***].

7.      RESTRICTIVE COVENANT

7.1     As consideration for Aviron agreeing to the amendment and restatement of
        this Agreement Evans shall not (and shall procure that no Associated
        Company shall) for so long as the [***] is in force and effect and for a
        period of [***] after the termination of the [***], [***], and Evans
        shall not [***], which have not been not authorised in writing by
        Aviron, including but not limited to any [***] and Evans shall not
        [***].

7.2     The undertaking in sub-clause 7.1 is considered by the parties to be
        reasonable in all the circumstances. If such undertaking should for any
        reason be held to be invalid but would have been held to be valid if
        part of the wording were deleted, the undertaking shall apply with such
        part of the wording deleted.

8.      ANNOUNCEMENTS AND PUBLICITY

        No announcement or circular or other publicity in connection with the
        subject matter of this Agreement (other than as permitted by this
        Agreement) shall be made by or on behalf of Evans and Aviron without the
        approval of the other as to its content, form and manner of publication
        (such approval not to be unreasonably withheld or delayed) save that any
        announcement, circular or other publicity required to be made or issued
        by Evans or Aviron pursuant to any legal or regulatory authority may be
        made or issued by Evans or Aviron without such approval. The parties
        shall consult together upon the form of any such announcement, circular
        or other publicity and the other party shall promptly provide such
        information and comment as the party issuing any such announcement,
        circular or other publicity may from time to time reasonably request.

9.      NOTICES

9.1     Any notice required to be given under this Agreement shall be in writing
        signed by (or by some person duly authorized by) the person giving it
        and may be served by leaving it or sending it by facsimile to the
        address of the relevant party set out in sub-clause 9.2. Any notice so
        served shall be deemed to have been received:

        (a)    if delivered personally, at the time of delivery; or

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       5
<PAGE>   8

        (b)    in the case of a notice sent by facsimile, if the notice was sent
               during the business hours of the addressee then on the day of
               transmission, and otherwise on the next following Business Day.

               For the purposes of this Clause "business hours" means the hours
               of 9.00 a.m. to 5.30 p.m. local time in the country of the
               addressee.

9.2     Any notice required to be given under this Agreement shall be sent:

        (a)    to Evans at: Florey House, Robert Robinson Avenue, Oxford,
               Oxfordshire OX4 4GA.

                      Facsimile No: 01865 332601

                      For the attention of: [***]

        (b)    to Aviron at: 297 North Bernardo Avenue, Mountain View,
               California 94043, USA.

                      Facsimile No: +1 (650) 919 2455

                      For the attention of: [***]

               or to such other address or facsimile number as is notified in
               writing from time to time by Evans or Aviron (as the case may be)
               to the other party to this Agreement.

9.3     Aviron irrevocably agrees that any writ, summons, claim form, order,
        judgment, or other process issued out of the courts of [***] in
        connection with any proceedings (a "Service Document") may be
        sufficiently and effectively served on it by the service on [***], if no
        replacement agent has been appointed and notified to Evans pursuant to
        sub-clause 9.3(b) or on the replacement agent if one has been appointed
        and notified to Evans.

        (a)    Any Service Document served pursuant to this clause shall be
               marked for the attention of:

               (i)    [***] or

               (ii)   such other person as is appointed as agent for service
                      pursuant to clause 9.3.

        (b)    If the agent referred to in sub-clause 93(a) (or any replacement
               agent appointed pursuant to this sub-clause) at any time ceases
               for any reason (including its dissolution) to act as Aviron's
               agent for service, Aviron shall promptly and irrevocably appoint
               another person with an address for service in [***] to be its
               agent for service on the terms of this clause and promptly notify
               Evans of the replacement's name and address.

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       6
<PAGE>   9

        (c)    A copy of any Service Document served on an agent pursuant to
               this clause shall be sent by post to Accrington at its address
               for the time being for the service of notices and other
               communications under this clause 9.

10.     COUNTERPARTS

This Agreement may be executed in two or more counterparts, each of which shall
be deemed to be an original, and which together shall constitute one and the
same Agreement. Unless otherwise provided in this Agreement, this Agreement
shall become effective and be dated (and each counterpart shall be dated) on the
date on which this Agreement (or a counterpart of this Agreement) is signed by
the last of the parties to execute this Agreement or, as the case may be, a
counterpart thereof.

11.     VARIATION

No variation of this Agreement shall be effective unless made in writing and
signed by or on behalf of each of the parties.

12.     COSTS

The parties shall pay their own costs and expenses in relation to the
preparation, execution and carrying into effect of this Agreement.

13.     SEVERANCE

If at any time any provision of this Agreement is or becomes invalid or illegal
in any respect, such provision shall be deemed to be severed from this Agreement
but the validity, legality and enforceability of the remaining provisions of
this Agreement shall not be affected or impaired thereby.

14.     WAIVERS

A failure by any party to exercise and any delay, forbearance or indulgence by
any party in exercising any right, power or remedy under this Agreement shall
not operate as a waiver of that night, power or remedy or preclude its exercise
at any subsequent time or on any subsequent occasion. The single or partial
exercise of any right, power or remedy shall not preclude any other or further
exercise of that right, power or remedy. No custom or practice of the parties at
variance with the terms of this Agreement shall constitute a waiver of the
rights of any party under this Agreement. The rights, powers and remedies
provided in this Agreement are cumulative and not exclusive of any rights,
powers or remedies provided by law.

15.     APPLICABLE LAW AND JURISDICTION

15.1    This Agreement shall be governed by [***] law and each of the parties
        submits to the exclusive jurisdiction of the [***].

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       7
<PAGE>   10

15.2    The parties irrevocably consent to any process in a legal action or
        proceedings in connection with this Agreement being served on it in
        accordance with the provisions of this Agreement relating to the service
        of notices. Nothing contained in this Agreement shall affect the right
        to serve process in any other manner permitted by law.

16.     [***]

The parties agree that the provisions of the [***]shall not apply to this
Agreement.

17.     ASSIGNMENT

[***] party may assign [***] its rights or delegate [***] its obligations under
this Agreement (other than [***] as the case may be provided that such assignee
[***] and provided further that before such assignee [***] will procure that the
benefit of this Agreement is re-assigned to [***] or (upon giving further
written notice to [***]) to [***] (subject always to the foregoing provisions of
this clause) [***] the prior written consent of [***], except as expressly
provided herein.

18.     [***]

18.1    Notwithstanding anything contained in this Agreement, if any of the
        amounts payable by Aviron to Evans under this Agreement are expressed to
        be [***] then [***] shall only be payable [***] if:

        (a)    [***] on such sums or amounts; and

        (b)    a proper [***] invoice is submitted to [***].

18.2    If [***] under this Agreement, in accordance with clause 18.1, or,
        notwithstanding clause 18.1, if (as applicable) no ruling under clause
        18.3 has been received to the effect that [***] in respect of any
        relevant amount by the date on which any [***] under this Agreement,
        then it shall be [***] on the date of this Agreement within 14 business
        days of the date of this Agreement and in any other case on the date on
        which [***].

18.3

        (a)    The parties take the view that the supplies under this Agreement
               should be treated as [***] and agree that [***] shall prepare a
               [***] to this effect. This [***] shall be sent first to [***] or
               its agents for approval (such approval not to be unreasonably
               withheld or delayed) and once approved shall be sent to [***].

        (b)    The parties shall use their reasonable endeavours to ensure that
               the [***] is obtained on or before the date of this Agreement. If
               no [***] by the date of this Agreement the parties should use
               their reasonable endeavours to ensure that within 5 Business Days
               of the date of this Agreement a letter is sent to [***].

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       8
<PAGE>   11

               [***] shall send a copy of any [***] to [***] and [***] within 5
               Business Days of receipt of it from [***].

        (c)    If no such [***] has been obtained by the time that [***] is due
               to [***] which includes a [***] it may notify [***] that it has
               [***] on a transaction which may be treated as a [***].

18.4

        (a)    If [***] that any or all of the [***] which are being treated as
               [***] under any of the Transaction Agreements constitute a [***]
               or [***] or a [***]:

               (i)    [***], if it has not submitted a [***] on which it has
                      accounted for the [***] on the date on which such [***],
                      will forthwith issue [***] which has been [***] in which
                      case [***] will on the date of [***] the [***] detailed in
                      the applicable [***]; or

               (ii)   [***], if it has submitted a [***] on which the [***] has
                      been accounted for, will make an [***] as appropriate for
                      recovery of the applicable [***] from [***] and will
                      account to [***] on the date of such [***] and will issue
                      at that date [***] which has been [***].

        (b)    For the avoidance of doubt any failure by [***] to comply with
               any conditions detailed in the [***] under which a [***] is made
               (such that [***] do not receive a [***] or only receive a [***]
               from [***]) will not affect the obligation of [***] to refund to
               [***] any [***] and for the purposes of clause 18.4 (a) (ii) it
               shall be regarded as having [***] on the date on which it would
               have [***] were it not for such failure.

IN WITNESS WHEREOF this Agreement has been executed by the duly authorised
representatives of the parties the day and the year first above written.

                                            EVANS VACCINES LIMITED

                                            By: /s/ C.S.W. Swingland
                                                --------------------------------
                                            Name: C.S.W. Swingland
                                            Title:  Director

                                     AVIRON

                                            By: /s/ Fred Kurland
                                                --------------------------------
                                            Name:  Fred Kurland
                                            Title:  SVP & CFO

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       9<PAGE>   1
                                                                   EXHIBIT 10.48

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                              DATED 11 OCTOBER 2000

                          -----------------------------

                           EVANS VACCINES LIMITED (1)

                                       AND

                              AVIRON UK LIMITED (2)

                          -----------------------------

                                    KNOW HOW
                                LICENCE AGREEMENT

                          -----------------------------

                               CMS CAMERON MCKENNA
                                   MITRE HOUSE
                              160 ALDERSGATE STREET
                                LONDON EC1A 4DD)

                              T +44(0)20 7367 3000
                              F +44(0)20 7367 2000

<PAGE>   2

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                            PAGE
                                                                            ----
<S>     <C>                                                                 <C>
1.      Definitions And Interpretation.........................................2

2.      Licence................................................................6

3.      Payments...............................................................6

4.      Intellectual Property..................................................7

5.      Warranties and Liability...............................................7

6.      Confidentiality and Security...........................................8

7.      Inspections............................................................9

8.      Improvements...........................................................9

9.      Miscellaneous..........................................................9

10.     [***].................................................................11

11.     [***].................................................................11
</TABLE>

                                       i
<PAGE>   3

THIS AGREEMENT is made the 11th day of October 2000

BETWEEN

(1)     EVANS VACCINES LIMITED whose registered office is at Florey House, 4
        Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA (the
        "LICENSOR"); and

(2)     AVIRON UK LIMITED whose registered office is at Carmelite, 50 Victoria
        Embankment, London EC4V 0DX (the "LICENSEE").

RECITALS

(A)     The Licensor is at the date of this Agreement the proprietor of the
        Evans Process Technology (as defined below).

(B)     The Licensor has agreed to license to the Licensee its rights in the
        Evans Process Technology on the terms and subject to the conditions of
        this Agreement.

(C)     The Licensee has agreed to make the Payments (as defined below) stated
        in this Agreement for a licence of the Evans Process Technology.

IT IS AGREED as follows:-

1.      DEFINITIONS AND INTERPRETATION

1.1     In this Agreement the following words and phrases shall have the
        following meanings unless the context requires otherwise:-

        "AGENCY" means any governmental body responsible for licensing of the
        Finished Product (as defined in the Shared Services Agreement) for
        commercial sale and the licensing of premises and facilities of the
        manufacturer.

        "AGREEMENT" means this agreement as varied from time to time in
        accordance with the provisions of this agreement.

        "ASSOCIATED COMPANIES" means in respect of any party, any company which
        at the relevant time is a Subsidiary of that party's ultimate Holding
        Company or any Subsidiary of such a subsidiary provided always that in
        the case of the Licensee any licensee or licensor of it in connection
        with the Vaccine shall be included in this definition of "Associated
        Company".

        "CAIV PRODUCT" means a live, attenuated intranasally deliverable
        cold-adapted influenza vaccine.

        "COMMENCEMENT DATE" means the date of this Agreement.

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<PAGE>   4

        "COMPETENT AUTHORITY" means any local or national agency, authority,
        department, inspectorate, minister, ministry official, parliament or
        public or statutory person (whether autonomous or not) of or of any
        government of any country having jurisdiction over either any of the
        activities contemplated by this Agreement or the Parties, including the
        European Commission and the European Court of justice.

        "EVANS PROCESS TECHNOLOGY" means all Know-How, technology developed,
        owned, controlled or licensed (with the right to sub-license) by Evans
        pertaining to [***] or any other formulation of a product [***] which is
        not in the public domain or otherwise generally available to the public
        including any Improvements.

        "IMPROVEMENT" means any improvement, enhancement, derivative, work or
        other modifications to the Evans Process Technology or its method of
        manufacture which is made by Evans within 5 years from the date of this
        Agreement.

        "INTELLECTUAL PROPERTY" means patents, know-how, registered and
        unregistered trade marks and service marks (including any trade, brand
        or business names), domain names, registered designs, design rights,
        utility models, copyright (including all such rights in computer
        software, and any databases), moral rights and topography rights (in
        each case for the full period thereof and all extensions and renewals
        thereof), applications for any of the foregoing and the right to apply
        for any of the foregoing in any part of the world and any similar rights
        situated in any country;

        "INTERMEDIATE PRODUCT" means Monovalent Virus Harvest and/or NAF
        manufactured according to and conforming with the Specifications which
        is intended for use in the manufacture of the Vaccine.

        "KNOW HOW" means unpatented technical and other information which is not
        in the public domain, including information comprising or relating to
        concepts, discoveries, data, formulae, ideas, inventions, procedures for
        experiments and tests and results of experimentation and testing,
        including results of research or development process including any
        industrial information and techniques likely to assist in the
        manufacturing or processing of goods and materials.

        "MASTER DONOR STRAINS" means the live attenuated influenza strains
        derived by Dr Maassab and designated Type A/Ann Arbor/6/60 - H2N2 and
        Type B/Ann Arbor/ 1/66, exclusively licensed from the University of
        Michigan to the Licensee and which are used by the Licensee to produce
        Master Virus Seeds.

        "MASTER VIRUS SEEDS" means certain reassortants produced by the Licensee
        from the Master Donor Strains.

        "MONOVALENT VIRUS HARVEST" means each of the three virus strains to be
        incorporated in the Vaccine for a given flu season in bulk form.

        "NAF" means "Normal Allentoic Fluid" used as a dilutant in the Vaccine
        and/or any other materials used as a dilutant in the Vaccine.

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       3
<PAGE>   5

        "PARTIES" means the Licensor and the Licensee and "PARTY" shall mean
        either one of them.

        "RESTRICTED INFORMATION AND MATERIALS" means (i) Master Donor Strains,
        Master Virus Seeds, Manufacturing Working Virus Seeds, Monovalent Virus
        Harvest and NAF (the "STRAINS"); (ii) all Technical Information
        (together with the Strains, the "AVIRON RESTRICTED MATERIAL"); (iii) all
        information relating to the Discloser's (as defined below) business that
        is identified at the time of disclosure as confidential; and (iv) all
        information arising pursuant to this Agreement, and the amended and
        restated contract manufacturing agreement dated 7 June 1999 between the
        Licensor (as assignee of Medeva Pharma Limited ("MEDEVA")) (1) and
        Aviron (2), disclosed by one party to this Agreement (the "DISCLOSER")
        to the other or to any Agency or to any third party (in each case by one
        Party at the request of the other) (the "RECIPIENT") in connection with
        this Agreement, excluding any such information which:

        (a)    is or was already known to the Recipient at the time of
               disclosure by the Discloser as evidenced by the written records
               of the Recipient; or

        (b)    was at the time of such disclosure or communication by the
               Discloser or thereafter becomes or became published, accessible
               to the public or otherwise in the public domain other than
               through any act or omission of the Recipient; or

        (c)    must be disclosed to government inspectors in the discharge of
               statutory obligations provided that before disclosure the
               Recipient shall use reasonable endeavours as it would in respect
               of its own Restricted Information and Materials to obtain from
               such government inspectors any assurances as regards
               confidentiality as may be afforded to such information in the
               circumstances; or

        (d)    must be disclosed by the Recipient to the relevant Competent
               Authority in the course of applying for, obtaining or maintaining
               regulatory approval provided that before disclosure the Recipient
               shall use reasonable endeavours as it would in respect of its own
               Restricted Information and Materials to obtain from such
               Competent Authority any assurances as regards confidentiality as
               may be afforded to such information in the circumstances; or

        (e)    is hereafter disclosed to the Recipient by a third party, who to
               the knowledge of the Recipient does not have any obligations of
               confidentiality to any third party or who has not, to the actual
               knowledge of the Recipient, derived it directly or indirectly
               from the Discloser provided that before disclosure the Recipient
               shall use reasonable endeavours as it would in respect of its own
               Restricted Information and Materials to obtain from such third
               party any assurances as regards confidentiality as may be
               afforded to such information in the circumstances; or

        (f)    is required to be disclosed by law provided that before
               disclosure the Recipient shall use reasonable endeavours as it
               would in respect of its own Restricted Information and Materials
               to obtain any assurances from the recipient as regards
               confidentiality as may be afforded to such information in the
               circumstances.

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       4
<PAGE>   6

        "SHARED SERVICES AGREEMENT" means the shared services agreement dated on
        or about the date of this Agreement between the Parties.

        "SPECIFICATIONS" means requirements and specifications for the
        Intermediate Product and its manufacture as provided by the Licensee to
        the Licensor from time to time.

        "SUBSIDIARY" OR "HOLDING COMPANY" shall have the meaning ascribed to
        such expressions by Section 736 of the Companies Act 1985.

        "TECHNICAL INFORMATION" means all registration data, know-how,
        experience, formulation, manufacturing instructions, standard operating
        procedures, policies, instructions, standards, methods, test and trial
        results, manufacturing and formulation processes, hazard assessments,
        quality control standards, formulae, specifications, storage and data,
        samples, drawings, designs, description of packaging materials and all
        other relevant information relating to the Intermediate Product or its
        design, manufacture, formation, handling, storage, testing and use
        and/or Master Donor Strains and/or Master Virus Seeds.

        "TRANSACTION AGREEMENTS" shall have the meaning ascribed thereto in the
        Transfer Agreement.

        "TRANSFER AGREEMENT" means the agreement dated on or about the date of
        this Agreement between the Parties relating to certain employees of the
        Licensor.

        "VAT" means value added tax under the VATAct 1994 or any similar tax
        from time to time replacing it or performing a similar function.

        "VATA 1994" means the Value Added Tax Act 1994.

        "VACCINE" means the Licensee's CAIV Product.

1.2     In this Agreement:

        1.2.1  unless the context otherwise requires all references to a
               particular Clause or paragraph shall be a reference to that
               Clause or paragraph, in or to this Agreement as the same may be
               amended from time to time pursuant to this Agreement;

        1.2.2  the table of contents and headings are inserted for convenience
               only and shall be ignored in construing this Agreement;

        1.2.3  unless the contrary intention appears words importing the
               masculine gender shall include the feminine and vice versa and
               words in the singular include the plural and vice versa;

        1.2.4  unless the contrary intention appears words denoting persons
               shall include any individual, partnership, company, corporation,
               joint venture, trust, association,

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       5
<PAGE>   7

               organisation or other entity, in each case whether or not having
               separate legal personality;

        1.2.5  reference to the words "include" or "including" are to be
               construed without limitation to the generality of the preceding
               words; and

        1.2.6  reference to any statute or regulation includes any modification
               or re-enactment of that statute or regulation.

2.      LICENCE

2.1     The Licensor hereby grants to the Licensee a worldwide, [***],
        irrevocable, sub-licenseable (solely as provided in Clause 2.2) [***]
        licence under Evans Process Technology to make, have made, use, import,
        offer for sale and sell CAIV Products and for the avoidance of doubt the
        Licensee may utilise those aspects of the Evans Process Technology that
        are in the public domain or otherwise generally available without any
        restrictions including, without limitation, to make, have made, use,
        import, offer for sale, sell and have sold products other than CAIV
        Products. If the Licensee is in any doubt as to whether or not a
        particular aspect of the Evans Process Technology is in the public
        domain, or otherwise generally available without any restrictions, it
        shall provide to the Licensor a [***] setting forth sufficient detail to
        allow the Licensor to [***] and the Licensor shall, within [***] of
        receipt of such [***], provide to the Licensee an [***]; provided that
        if the parties disagree whether or not a particular aspect of Evans
        Process Technology is in the public domain, the matter shall be [***]
        and, thereafter, if the matter is still unresolved, either Party may
        [***].

2.2     The Licensee shall have the right to grant sub-licences under the
        licence granted under Clause 2.1 above to its Associated Companies,
        contract manufacturers and the licensees of CAIV Products provided that
        any sub-licences granted pursuant to this Clause 2.2 shall be on such
        terms and conditions [***] as set out in [***] and the Licensee shall be
        [***] for the [***] of any sub-licensee of the licence.

2.3     As soon as reasonably practicable following the Commencement Date, the
        Licensor shall disclose, deliver and make fully available to the
        Licensee in the form reasonably requested by the Licensee, all of the
        Know How relating to the Evans Process Technology.

3.      PAYMENTS

3.1     The Licensee shall pay to the Licensor in consideration of the rights
        granted to the Licensee under this Agreement the aggregate sum of
        $34,250,000 payable in the following amounts and on the following dates
        (the "PAYMENTS"):-

        3.1.1  US$15,000,000 on the Commencement Date;

        3.1.2  US$3,850,000 on [***] 2001;

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       6
<PAGE>   8

        3.1.3  US$3,850,000 on [***] 2002;

        3.1.4  US$3,850,000 on [***] 2003;

        3.1.5  US$3,850,000 on [***] 2004; and

        3.1.6  US$3,850,000 on [***] 2005.

3.2     All payments to the Licensor under the terms of this Agreement are
        expressed to be [***] and the Licensee shall pay to the Licensor [***]
        on each Payment or other sum paid to it hereunder.

3.3     If any sum due for payment under this agreement is not paid on the due
        date the Licensee shall [***] for the time being.

3.4     The Parties hereby agree to notify Her Majesty's Inspector of Taxes of
        an election (no later than [***] after the Commencement Date) to the
        effect that [***] shall not apply to the acquisition and disposal of the
        Know-How in a form to be agreed between the parties (acting reasonably).

4.      INTELLECTUAL PROPERTY

4.1     The Licensor agrees and acknowledges that, save as specifically provided
        in this Agreement it has and shall have following the date of this
        Agreement no right or interest, whether legal, equitable or moral in any
        Intellectual Property relating directly to or arising from the
        Intermediate Product and for the avoidance of doubt, the Licensor hereby
        waives any such right or interest.

4.2     Nothing in this Agreement shall operate to transfer ownership of any
        right in the Evans Process Technology to the Licensee.

5.      WARRANTIES AND LIABILITY

5.1     Each of the Licensor and the Licensee warrants that it is able to enter
        into this Agreement and is not restricted by any provisions of any
        agreements of any nature which prevent it from carrying out this
        Agreement fully according to its terms.

5.2     The Licensor warrants that: (i) the Licensor has not licensed or
        assigned any interest in the Evans Process Technology to any third party
        that would prevent the Licensee's full enjoyment of its rights
        hereunder; (ii) the Licensor possesses sufficient right, title and
        interest in and to the Evans Process Technology as provided herein; and
        (iii) it has not received and is not aware that [***] has received any
        written notice that [***] infringes any third party intellectual
        property rights.

5.3     Subject to Clauses 5.5 and 5.6, the Licensee shall indemnify and keep
        indemnified and hold harmless the Licensor and its Associated Companies
        against any and all losses, damages, costs and expenses suffered or
        incurred by the Licensor as a direct result of any

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       7
<PAGE>   9

        [***] arising out of the use of the [***] by the Licensee and its
        Associated Companies under this Agreement provided that the Licensee
        shall have no obligation to indemnify the Licensor for any claims due to
        the Licensor's [***] of Know-How pursuant to Clause 2.3.

5.4     Subject to Clauses 5.5 and 5.6, the Licensor shall indemnify and keep
        indemnified and hold harmless the Licensee and its Associated Companies
        against any and all losses, damages, costs and expenses suffered or
        incurred by the Licensee as a direct result of any [***] based on [***].

5.5     Neither Party shall be liable to the other in contract, tort,
        negligence, breach of statutory duty or otherwise for any loss, damage,
        costs or expenses of any nature whatsoever incurred or suffered by the
        other of an [***] including any [***].

5.6     The provisions of this clause shall apply to any claim by [***] against
        the Licensee or the Licensor (as the case may be) in respect of a matter
        which has given rise to a claim pursuant to the indemnities given in
        Clauses 5.3 and 5.4 above (in each case a "RELEVANT CLAIM"). The
        Licensee or the Licensor (as the case may be) shall as soon as
        reasonably practical give written notice of the Relevant Claim and
        subject to the Licensor or the Licensee (as the case may be)
        acknowledging, in writing, its [***] to the Licensee for such Relevant
        Claim pursuant to Clause 5.3 or 5.4 (as the case may be) and the
        Licensee or the Licensor (as the case may be) being fully indemnified
        against any reasonable costs, liabilities and expenses thereby incurred:

        5.6.1  [***];

        5.6.2  [***];

        5.6.3  [***];

        5.6.4  [***];

        5.6.5  [***];

        5.6.6  [***]:

               (a)    [***];

               (b)    [***];

        Provided always that nothing in this Clause 5.6 shall require the
        Licensee to take any action which is reasonably likely to have a [***]
        on the [***] of the Licensee and its Associated Companies or Licensor
        and its Associated Companies (as the case may be).

6.      CONFIDENTIALITY AND SECURITY

6.1     The Recipient undertakes to keep confidential all Restricted Information
        and Materials received by it directly or indirectly from the Discloser
        or obtained by it pursuant to the

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       8
<PAGE>   10

        performance of this Agreement and not to use such Restricted Information
        and Materials except as provided in this Agreement. The obligations set
        forth in this Clause 6.1 shall apply during the period of this Agreement
        and for a period of [***] after the termination of this Agreement.

6.2     The Recipient shall allow access to the Discloser's Restricted
        Information and Materials exclusively to those of its employees who have
        reasonable need to see and use it for the purposes of this Agreement and
        shall inform each of such employees of the confidential nature of the
        Restricted Information and Materials and of the obligations on the
        Recipient with respect to such Restricted Information and Materials and
        shall ensure that each of its employees having access to the Restricted
        Information and Materials is contractually bound by obligations of
        confidentiality and shall take such steps as may be necessary to enforce
        such obligations.

6.3     On the expiry or termination of this Agreement, the Recipient will
        return to the Discloser all Restricted Information and Materials of the
        Discloser in its possession and the Recipient shall, save in respect of
        the Aviron Restricted Material have the option to retain (1) copy, but
        shall not make any further use of that information save for record
        keeping purposes or in order to comply with regulatory requirements from
        time to time.

6.4     In this Clause 6 references to the Discloser or Recipient shall be
        deemed to include any Associated Companies of that party.

7.      INSPECTIONS

        The provisions of Clause 3 (Inspections) of the Shared Services
        Agreement shall apply to this Agreement as they apply to that Agreement.

8.      IMPROVEMENTS

        Any Improvement developed by [***] shall be owned by [***] and [***]
        shall own all intellectual property rights in the Improvement, provided
        always that in the event that [***] develops any Improvements directly
        as a result of the performance by [***] of the [***] (as defined in the
        [***]), [***] agrees to notify [***] of the existence of such
        Improvements and grants to [***] a [***] licence to use such
        Improvements on substantially the same terms of this Agreement.

9.      MISCELLANEOUS

9.1     The Licensor [***] assign [***] its rights or delegate [***] its
        obligations under this Agreement to its Associated Companies, provided
        that such assignee [***] and provided further that before such assignee
        [***]will procure that the benefit of this Agreement is re-assigned to
        [***] or (upon giving further written notice to [***]) to [***] (subject
        always to the foregoing provisions of this clause) [***] the prior
        written consent of [***], except as expressly provided herein.

9.2     The Licensee [***] assign the benefit of its rights or interest in this
        Agreement [***].

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       9
<PAGE>   11

9.3     The validity, construction and interpretation of this Agreement and any
        determination of the performance which it requires shall be governed by
        [***]. All disputes between the Parties arising out of the circumstances
        and relationships contemplated by this Agreement including disputes
        relating to the validity, construction or interpretation of this
        Agreement, and including disputes relating to pre-contractual
        representations, which result in any action or proceeding shall be
        subject to the exclusive jurisdiction of the [***].

9.4     Save as expressly provided in this Agreement nothing herein takes away
        from the Parties or constitutes a waiver by any party of any of their
        rights or remedies under common law, statute or otherwise.

9.5     If the whole or any part of this Agreement is or becomes or is declared
        illegal, invalid or unenforceable for any reason (including both by
        reason of the provisions of any legislation and also by reason of any
        decision of any court or competent authority which either has
        jurisdiction over this Agreement or has jurisdiction over any of the
        Parties):

        9.5.1  (except as provided by Clause 9.6) in the case of the illegality
               invalidity or unenforceability of the whole of this Agreement, it
               shall terminate forthwith: or

        9.5.2  in the case of the illegality, invalidity or unenforceability of
               part of this Agreement, part shall be severed from this Agreement
               and that illegality, invalidity or unenforceability shall not in
               any way whatsoever prejudice or affect the remaining parts of
               this Agreement which shall continue in full force and effect.

9.6     This Agreement constitutes the entire agreement and understanding
        between the Parties and supersedes all prior oral or written
        understandings, arrangements, representations or agreements between them
        relating to the subject matter of this Agreement provided that this does
        not remove any right of action by either Party, in respect of any
        fraudulent misrepresentation, fraudulent concealment or other fraudulent
        action. No director, employee or agent of any Party is authorised to
        make any representation or warranty to any other Party not contained in
        this Agreement, and each Party acknowledges that it has not relied on
        any such oral or written representations or warranties.

9.7     All notices to be given pursuant to this Agreement shall be given in
        accordance with Clause 11 (Notices) of the Shared Services Agreement.

9.8     The activities of the Parties contemplated pursuant to this Agreement
        shall not constitute a partnership and neither party has the authority
        to bind the other Party in anyway except provided in this Agreement.

9.9     Each Party shall bear its own legal costs and other expenses incurred in
        the negotiation, preparation, execution and implementation of this
        Agreement.

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       10
<PAGE>   12

9.10    No announcement or circular or other publicity in connection with the
        subject matter of this Agreement (other than as permitted by this
        Agreement) shall be made by or on behalf of the Licensor and the
        Licensee without the approval of the other as to its content, form and
        manner of publication (such approval not to be unreasonably withheld or
        delayed) save that any announcement, circular or other publicity
        required to be made or issued by the Licensor or the Licensee pursuant
        to any legal or regulatory authority may be made or issued by the
        Licensor or the Licensee without such approval. The Parties shall
        consult together upon the form of any such announcement, circular or
        other publicity and the other party shall promptly provide such
        information and comment as the party issuing any such announcement,
        circular or other publicity may from time to time reasonably request.

9.11    The [***] remedy of the Licensee for a breach of this Agreement: shall
        be [***] and the Licensee shall [***] in any circumstances or at any
        time.

10.     [***]

        The Parties agree that the provisions of the [***] shall not apply to
        this Agreement.

11.     [***]

11.1    Notwithstanding anything contained in this Agreement, if any of the
        amounts payable by the Licensee to the Licensor are expressed to be
        [***] then [***] shall only be payable [***] if:

        11.1.1 [***] on such sums or amounts; and

        11.1.2 a proper [***] invoice is submitted to [***].

11.2    If [***] under this Agreement, in accordance with clause 11.1, or,
        notwithstanding clause 11.1, if (as applicable) no ruling under clause
        11.3 has been received to the effect that [***] in respect of any
        relevant amount by the date on which any [***] under this Agreement,
        then it shall be [***] on the date of this Agreement within 14 business
        days of the date of this Agreement and in any other case on the date on
        which [***].

11.3

        11.3.1 The Parties consider that the transactions detailed in the
               Transaction Agreements shall not together constitute a [***] or
               [***] for [***] purposes, and agree that the Licensor shall
               prepare a [***] to this effect. This [***] shall be sent first to
               [***] for approval (such approval not to be unreasonably withheld
               or delayed) and once approved shall be sent to [***].

        11.3.2 The Parties shall use their reasonable endeavours to ensure that
               the [***] is obtained on or before the date of this Agreement. If
               no [***] by the date of this Agreement the Parties should use
               their reasonable endeavours to ensure that within 5 business days
               of the date of this Agreement a letter is sent to [***]. The

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       11
<PAGE>   13

               [***] shall send a copy of any [***] to [***] and the [***]
               within 5 business days of receipt of it from Customs.

        11.3.3 If no such [***] has been obtained by the time that [***] and the
               [***] (as the case may be) are due to [***] which include a [***]
               they may notify [***] that they have [***] on a transfer of
               assets which has not been treated as [***].

11.4

        11.4.1 If [***] that any or all of the [***] which are being treated as
               [***] under this Agreement constitute a [***] or [***] or a
               [***]:

               (a)    the [***], if it has not submitted a [***] on which it has
                      accounted for the [***] on the date on which such [***],
                      will forthwith issue [***] which has been [***] in which
                      case the [***] will on the date of [***] as applicable the
                      [***] detailed in the applicable [***]; or

               (b)    the [***], if it has submitted a [***] on which the [***]
                      has been accounted for, will make an [***] as appropriate
                      for recovery of the applicable [***] from [***] and will
                      account to [***] as appropriate on the date of such [***]
                      and will issue at that date [***] which has been [***].

        11.4.2 For the avoidance of doubt any failure by [***] to comply with
               any conditions detailed in the [***] under which a [***] is made
               (such that [***] does not receive a [***] or only receives a
               [***] from [***]) will not affect the obligation of [***] to
               refund to [***] any [***] and for the purposes of clause 11.4.1
               (a) it shall be regarded as having [***] on the date on which it
               would have [***] were it not for such failure.

IN WITNESS WHEREOF the Parties have executed this document as an agreement the
day and year first above written.

SIGNED by C.S.W.  Swingland        )              /s/ C.S.W. Swingland
for and on behalf of               )
EVANS VACCINES LIMITED             )

SIGNED by                          )              /s/ Fred Kurland
for and on behalf of               )
AVIRON UK LIMITED

[***] - CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
[***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00022-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00022-of-00352.parquet"}]]